vTv Therapeutics (VTVT) Competitors $22.56 +0.39 (+1.74%) Closing price 03:58 PM EasternExtended Trading$22.42 -0.15 (-0.66%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. NMRA, FHTX, TECX, LXEO, MREO, ABEO, CADL, DBVT, ALLO, and EDITShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Neumora Therapeutics (NMRA), Foghorn Therapeutics (FHTX), Tectonic Therapeutic (TECX), Lexeo Therapeutics (LXEO), Mereo BioPharma Group (MREO), Abeona Therapeutics (ABEO), Candel Therapeutics (CADL), DBV Technologies (DBVT), Allogene Therapeutics (ALLO), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Its Competitors Neumora Therapeutics Foghorn Therapeutics Tectonic Therapeutic Lexeo Therapeutics Mereo BioPharma Group Abeona Therapeutics Candel Therapeutics DBV Technologies Allogene Therapeutics Editas Medicine Neumora Therapeutics (NASDAQ:NMRA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Do insiders and institutionals have more ownership in NMRA or VTVT? 47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 26.8% of Neumora Therapeutics shares are held by insiders. Comparatively, 4.2% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer NMRA or VTVT? In the previous week, vTv Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.91 beat vTv Therapeutics' score of 1.02 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neumora Therapeutics Very Positive vTv Therapeutics Positive Is NMRA or VTVT more profitable? Neumora Therapeutics' return on equity of -98.95% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -98.95% -87.68% vTv Therapeutics N/A -179.75%-55.91% Which has more risk and volatility, NMRA or VTVT? Neumora Therapeutics has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Which has stronger earnings and valuation, NMRA or VTVT? vTv Therapeutics has higher revenue and earnings than Neumora Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.57-1.08vTv Therapeutics$17K4,240.89-$18.46M-$3.12-7.23 Do analysts rate NMRA or VTVT? Neumora Therapeutics presently has a consensus price target of $7.14, suggesting a potential upside of 320.17%. vTv Therapeutics has a consensus price target of $35.50, suggesting a potential upside of 57.32%. Given Neumora Therapeutics' higher probable upside, equities analysts plainly believe Neumora Therapeutics is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNeumora Therapeutics beats vTv Therapeutics on 9 of the 14 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.10M$3.07B$5.65B$10.29BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-7.2320.7975.8626.14Price / Sales4,240.89404.26515.95170.63Price / CashN/A45.9137.5661.52Price / Book5.049.6312.886.30Net Income-$18.46M-$52.73M$3.29B$271.03M7 Day Performance4.47%0.66%-0.24%-0.13%1 Month Performance46.04%6.33%3.87%6.43%1 Year Performance71.21%18.99%68.39%28.82% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics2.3787 of 5 stars$22.57+1.7%$35.50+57.3%+69.0%$72.10M$17K-7.239NMRANeumora Therapeutics3.2163 of 5 stars$1.73-1.7%$7.14+312.9%-85.2%$285.02MN/A-1.10108Positive NewsGap DownFHTXFoghorn Therapeutics2.7606 of 5 stars$4.98-0.8%$10.67+114.2%-48.6%$283.78M$22.60M-4.18120Positive NewsTECXTectonic Therapeutic2.8444 of 5 stars$15.78+5.3%$80.29+408.8%-38.2%$280.31MN/A-3.91120LXEOLexeo Therapeutics2.5474 of 5 stars$5.31+3.1%$15.33+188.8%-26.0%$278.11M$650K-1.6358News CoverageMREOMereo BioPharma Group2.1748 of 5 stars$1.85+6.3%$7.40+300.0%-55.6%$276.66M$10M-26.4340Positive NewsABEOAbeona Therapeutics4.0334 of 5 stars$5.48+1.9%$19.50+255.8%-3.6%$275.88M$3.50M7.8390CADLCandel Therapeutics2.618 of 5 stars$5.23+8.7%$20.00+282.4%-22.8%$264.05M$120K-7.5860Positive NewsDBVTDBV Technologies2.4428 of 5 stars$9.50flat$14.75+55.3%+151.2%$260.25M$4.15M-1.9980ALLOAllogene Therapeutics3.2644 of 5 stars$1.17+0.9%$8.44+621.7%-53.9%$257.38M$20K-1.05310Positive NewsEDITEditas Medicine4.2373 of 5 stars$3.00+6.0%$5.10+70.0%-4.5%$254.47M$32.31M-1.05230Positive News Related Companies and Tools Related Companies NMRA Alternatives FHTX Alternatives TECX Alternatives LXEO Alternatives MREO Alternatives ABEO Alternatives CADL Alternatives DBVT Alternatives ALLO Alternatives EDIT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
